Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by fredgoodwinsonon Jan 11, 2020 5:58am
173 Views
Post# 30541647

RE:Had a contact with IR

RE:Had a contact with IR

Good post Oilminer - and best wishes for the Gym.

Definitive results on enduring CRs in at least 25 may not be received until late 2021 or beyond but wouldn`t write off the possibility of the Company issuing selective data much, much earlier.

 

The wording of ShuShu`s reply to Investclub was interesting:

 

‘Shushu said the Company wanted to stay within the guidelines of other PH2 trials and only release results of significance such as 25 patients needed for fast track…’

 

Note that these are the guidelines of other Phase II Trials and not (yet) the guidelines of this one. This leaves - as I suggested earlier - the option of that 3-month release but the Company is sensibly refraining from anything likely to compromise the IND approval.

 

It could be a different matter if we get to March and the FDA is still withholding. At that point the Company might choose to strategically release 3-month data from the Canadian trial for a sample of 6 to assuage safety concerns and hopefuly to include that magic ‘no clinical evidence or presence of disease’ kicker.

 

This would have positive consequences in either of two circumstances: 

 

If it appeared that the FDA were being unreasonably recalcitrant it would put pressure on them to grant approval.

 

If it appeared that there was no prospect of short-term FDA Approval it could substantially boost both Canadian recruitment and those seeking recruitment from south of the border - in other words it could save the Trial.

 

A good shot to have in your locker and for me (and IMHO DYOR) why the stock looks very attractive at these levels because by mid-March the 54c warrants will be out of the way the Company will itself know very well where the Trial is going and we will have either FDA approval or I believe this ann of 3-month Canadian data which in the absence of FDA approval the Company will have every right to make.Either of the last two should result in a substantial re-rating.

 

Patience will of course be required for the longer haul and for now the stock remains a shorter`s paradise but we are much closer to the finish than where we started. GLTA Longs.

 
Bullboard Posts